US-based ANI Pharmaceuticals has purchased the rights from AstraZeneca to market Atacand, Atacand HCT, Arimidex and Casodex tablets in the country.
The deal, which included new drug applications (NDAs) and a licence to the trademarks of the products, involves $46.5m in cash, royalties and sales-based milestones.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Atacand is formulated as an angiotensin II receptor blocker (ARB) for treating hypertension and heart failure, while Atacand HCT is an antagonist of the receptor, and a diuretic, hydrochlorothiazide.
An aromatase inhibitor, Arimidex is indicated for the treatment of post-menopausal women, and Casodex is used to block androgen receptor to treat metastatic prostate carcinoma.
ANI Pharmaceuticals president and CEO Arthur Przybyl said: “This acquisition complements our brand and generic strategies and further expands and diversifies our commercial portfolio.
“Importantly, ANI has the capability to manufacture and package all of the products at our containment facility in Baudette, MN.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The addition of these assets will be material to our revenue and EBITDA in 2018, and we plan to provide financial guidance for 2018 at the time of our next regularly scheduled earnings announcement.”
Under the deal, AstraZeneca will be responsible for the marketing and supply of these four products outside the US.
As per information, services and technology provider IMS Health, Atacand, Atacand HCT, Arimidex and Casodex together generated around $19m in sales in the US during the 12-month trialling through October last year.
